Operator: Good day, ladies and gentlemen. And welcome to the Avid Bioservices Second Quarter Fiscal 2023 Financial Results Conference Call. At this time all participants are in a listen-only mode.
Recorded Second Quarter Revenue of $34.8 Million Signed $26 Million in Net New Business Orders Resulting in a Backlog of $147 Million, an Increase of 23% Year-Over-Year Mammalian. | December 6, 2022
Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by
Accomplished Operations Professional Promoted from Role as Director of Project Engineering; Credited with Leading All of the Company’s Ongoing Facility.